From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents

Sarah K. Tasian; Judith M. Boer; Monique L. den Boer

doi:10.1016/j.ejcped.2025.100304

From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

This review aims to discuss similarities and dissimilarities between BCR::ABL1-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historically high-risk leukemias, modern laboratory diagnostics, current treatment approaches, potential causes of treatment failure, emerging new targeted therapies and immunotherapeutic approaches for patients will be discussed. While the primary focus of this review is upon children and adolescents with BCR::ABL1-positive and ABL-class ALL, extended knowledge from recent adult clinical trials will also be addressed.

Original language	English
Article number	100304
Journal	EJC Paediatric Oncology
Volume	6
DOIs	https://doi.org/10.1016/j.ejcped.2025.100304
Publication status	Published - Dec 2025

Keywords

ABL-class
Acute lymphoblastic leukemia
BCR::ABL1
BCR::ABL1-like
Children
Clinical trials
Genetics
Immunotherapy
Ph+
Ph-like
Targeted therapy
Tyrosine kinase inhibitor

Access to Document

10.1016/j.ejcped.2025.100304

Cite this

@article{e902ad15554a4161aaec727f9a756745,

title = "From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents",

abstract = "This review aims to discuss similarities and dissimilarities between BCR::ABL1-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historically high-risk leukemias, modern laboratory diagnostics, current treatment approaches, potential causes of treatment failure, emerging new targeted therapies and immunotherapeutic approaches for patients will be discussed. While the primary focus of this review is upon children and adolescents with BCR::ABL1-positive and ABL-class ALL, extended knowledge from recent adult clinical trials will also be addressed.",

keywords = "ABL-class, Acute lymphoblastic leukemia, BCR::ABL1, BCR::ABL1-like, Children, Clinical trials, Genetics, Immunotherapy, Ph+, Ph-like, Targeted therapy, Tyrosine kinase inhibitor",

author = "Tasian, \{Sarah K.\} and Boer, \{Judith M.\} and \{den Boer\}, \{Monique L.\}",

note = "Publisher Copyright: {\textcopyright} 2025 The Authors",

year = "2025",

month = dec,

doi = "10.1016/j.ejcped.2025.100304",

language = "English",

volume = "6",

journal = "EJC Paediatric Oncology",

issn = "2772-610X",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents

AU - Tasian, Sarah K.

AU - Boer, Judith M.

AU - den Boer, Monique L.

PY - 2025/12

Y1 - 2025/12

N2 - This review aims to discuss similarities and dissimilarities between BCR::ABL1-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historically high-risk leukemias, modern laboratory diagnostics, current treatment approaches, potential causes of treatment failure, emerging new targeted therapies and immunotherapeutic approaches for patients will be discussed. While the primary focus of this review is upon children and adolescents with BCR::ABL1-positive and ABL-class ALL, extended knowledge from recent adult clinical trials will also be addressed.

AB - This review aims to discuss similarities and dissimilarities between BCR::ABL1-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historically high-risk leukemias, modern laboratory diagnostics, current treatment approaches, potential causes of treatment failure, emerging new targeted therapies and immunotherapeutic approaches for patients will be discussed. While the primary focus of this review is upon children and adolescents with BCR::ABL1-positive and ABL-class ALL, extended knowledge from recent adult clinical trials will also be addressed.

KW - ABL-class

KW - Acute lymphoblastic leukemia

KW - BCR::ABL1

KW - BCR::ABL1-like

KW - Children

KW - Clinical trials

KW - Genetics

KW - Immunotherapy

KW - Ph+

KW - Ph-like

KW - Targeted therapy

KW - Tyrosine kinase inhibitor

UR - https://www.scopus.com/pages/publications/105009645673

UR - https://www.mendeley.com/catalogue/2ba00aba-f939-3a6e-ac5f-2f40cade70e1/

U2 - 10.1016/j.ejcped.2025.100304

DO - 10.1016/j.ejcped.2025.100304

M3 - Article

AN - SCOPUS:105009645673

SN - 2772-610X

VL - 6

JO - EJC Paediatric Oncology

JF - EJC Paediatric Oncology

M1 - 100304

ER -

From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents

Abstract

Keywords

Access to Document

Fingerprint

Cite this